Vimarsana
Biggest News Aggregation in the World

Page 19 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs - Vimarsana News

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market...

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering - Vimarsana News

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of...

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering - Vimarsana News

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors fo...

New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO) -February 01, 2024 at 01:06 am EST - Vimarsana News

New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO) -February 01, 2024 at 01:06 am EST

– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision – – Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three...

New long-term data for Roche's Vabysmo show sustained - Vimarsana News

New long-term data for Roche's Vabysmo show sustained

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to...